Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company that publicly describes its focus as the development of emavusertib (CA-4948), an orally available small molecule inhibitor of IRAK4 and, in some disclosures, FLT3. The Curis news stream highlights clinical progress, financing events, and corporate updates that shape the company’s development plans and capital position.
News about Curis frequently covers clinical data and study milestones for emavusertib. The company has reported interim results from its frontline AML triplet study (emavusertib with venetoclax and azacitidine), updates from the TakeAim Lymphoma and TakeAim Leukemia Phase 1/2 trials in PCNSL, AML and high-risk MDS, and presentations at major medical meetings such as the American Society of Hematology (ASH), the Society for Neuro-Oncology (SNO), and ASCO. These releases often describe response measures such as minimal residual disease status and safety observations within defined patient cohorts.
Investors following CRIS news will also see financing and capital markets announcements, including registered direct offerings, concurrent private placements of pre-funded and common warrants, and a PIPE financing involving Series B convertible preferred stock and multiple warrant series. Curis’s news has detailed the structure of these transactions, the gross proceeds, and the stated use of funds for research and development, general corporate purposes, and working capital.
Additional news items address corporate and regulatory developments, such as business updates, quarterly financial results, inducement equity grants, conference participation, and Nasdaq listing compliance notices related to market value of listed securities requirements. For readers tracking Curis, the CRIS news page provides an organized view of these clinical, financial, and listing-related disclosures in one place, allowing users to review how trial data, capital raises, and regulatory interactions evolve over time.
Curis (NASDAQ: CRIS) has announced a combined $7.0 million financing through a registered direct offering and concurrent private placement. The company will issue 1,538,460 shares of common stock in a registered direct offering and unregistered pre-funded warrants for up to 1,538,461 shares in a private placement.
The transaction includes Common Warrants to purchase up to 3,076,921 shares at an exercise price of $2.15 per share. The combined purchase price is $2.275 for one share and associated Common Warrant, and $2.265 for one Pre-Funded Warrant and associated Common Warrant. The offerings are expected to close around July 3, 2025.
Proceeds will support research, development, working capital, and general corporate purposes for Curis's development of emavusertib, an oral IRAK4 inhibitor.
Curis (NASDAQ: CRIS) has announced the approval of inducement stock options for its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy. The grant, approved by the Board of Directors, allows Dr. Hamdy to purchase 200,000 shares of Curis common stock at an exercise price equal to the closing price on May 1, 2025.
The stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary and an additional 6.25% vesting every three months thereafter, contingent on Dr. Hamdy's continued employment. The grant was made outside of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan as an inducement for Dr. Hamdy's employment.
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), has scheduled its first quarter 2025 financial results announcement for May 6, 2025, at 8:00 a.m. ET.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Investors can participate through:
- U.S. dial-in: (800)-836-8184
- International dial-in: (646)-357-8785
- Live audio webcast: Available on the Curis website's events & presentations section
Emavusertib, their key drug candidate, is an oral small molecule IRAK4 inhibitor. A replay of the conference call will be accessible at www.curis.com.
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference on April 9, 2025.
The company's President and CEO, James Dentzer, will engage in two key sessions: a fireside chat titled 'All Bets on IRAK4' at 4:30 PM ET, followed by a corporate presentation at 5:00 PM ET. Both events will be accessible via live webcast and archived replay through the Events & Presentations section of Curis's website.
Curis (NASDAQ: CRIS) reported its Q4 2024 business update and financial results. The company successfully concluded discussions with FDA and EMA regarding potential accelerated approval path for emavusertib in PCNSL, which received Orphan Drug Designation in both regions.
Key clinical highlights include:
- In BTKi-experienced PCNSL patients: 9 of 13 showed tumor reduction, including 6 objective responses
- In BTKi-naïve PCNSL patients: 5 of 6 demonstrated tumor reduction
- In R/R AML study: 10 of 19 evaluable patients achieved objective response
Financial results for Q4 2024:
- Net loss of $9.6 million ($1.25 per share)
- Revenue of $3.3 million from Erivedge royalties
- Cash position of $20.0 million as of December 31, 2024
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has scheduled its Q4 2024 financial results announcement for March 31, 2025, at 8:00 a.m. ET. The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Investors can access the call by dialing (800)-836-8184 from the US or (646)-357-8785 from other locations. A live webcast will be available on the Curis website's investor section, with a replay accessible at www.curis.com.
Curis (NASDAQ: CRIS) presented additional data from the TakeAim Leukemia study of emavusertib in relapsed/refractory Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting. The updated results include data from 21 patients with FLT3 mutation treated at the Recommended Phase 2 Dose of 300 mg BID.
Among 19 response-evaluable patients, 10 showed objective responses: 6 complete remissions (CR), 2 CR with incomplete/partial hematological recovery, and 2 morphologic leukemia-free state. Prior therapies of responders included Venetoclax, HMA, and FLT3i. Two patients proceeded to allogenic stem cell transplantation, with 7 of 10 responses observed at first assessment.
Curis Inc (NASDAQ: CRIS) reported Q3 2024 financial results with a net loss of $10.1 million ($1.70 per share), compared to $12.2 million in Q3 2023. Revenues were $2.9 million, primarily from Erivedge® royalties. The company completed a registered direct offering with net proceeds of $10.8 million. Clinical progress includes promising data from the TakeAim Lymphoma study, showing 3 complete responses and 1 unconfirmed complete response in PCNSL patients. Cash position stands at $31.6 million, expected to fund operations into mid-2025.
Curis (NASDAQ: CRIS) has announced it will release its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. The biotechnology company, which focuses on developing emavusertib (CA-4948), an oral IRAK4 inhibitor, will host a conference call and webcast at 8:30 a.m. ET on the same day. Participants can join via phone or access the live audio webcast through the investor section of the Curis website.